Observational, Prospective, Parallel Cohort Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea on a Background Therapy of Metformin With or Without a DPP-4 Inhibitor During Ramadan Fasting in Patients With Type 2 Diabetes

Trial Profile

Observational, Prospective, Parallel Cohort Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea on a Background Therapy of Metformin With or Without a DPP-4 Inhibitor During Ramadan Fasting in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CRATOS
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 08 Dec 2017 Results of pooled analysis this and other phase III study assessing safety and tolerability of canagliflozin in type 2 diabetes patients living in hot climates and fasting during Ramadan presented at the 2017 Congress of the International Diabetes Federation.
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 29 Aug 2017 Results published in the International Journal of Clinical Practice.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top